Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesPCRX -1.39%80 3-Year EPS without NRI Growth Rate is 0.80% as of Jun. 2026, which is 92% below its 10-year median of 9.45. GuruFocus rates PCRX with a GF Score™ of 80/100 and a GF Value™ of $29.31 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 782 Drug Manufacturers companies, Pacira BioSciences ranks worse than 62.92% on this metric.
During the past 12 months, Pacira BioSciences's average EPS without NRI Growth Rate was 10.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 0.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 0.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Pacira BioSciences was 119.10% per year. The lowest was -20.50% per year. And the median was 9.45% per year.
Pacira BioSciences (NAS:PCRX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Pacira BioSciences 3-Year EPS without NRI Growth Rate Related Terms
PCRX vs AMPH, COLL, IRWD: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's 3-Year EPS without NRI Growth Rate falls into.
Pacira BioSciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.80% mean?
Pacira BioSciences (PCRX) has a 3-Year EPS without NRI Growth Rate of 0.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pacira BioSciences and its competitors. This is 92% below median its historical median of 9.45. According to the industry distribution chart, Pacira BioSciences ranks #492 out of 782 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Pacira BioSciences' 3-Year EPS without NRI Growth Rate too high?
Pacira BioSciences' current 3-Year EPS without NRI Growth Rate of 0.80% is 92% below median its 10-year median of 9.45. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Pacira BioSciences' value of 0.80% is 91.8% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #492 out of 782 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' 3-Year EPS without NRI Growth Rate compare to AMPH and COLL?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #492 out of 782 companies for 3-Year EPS without NRI Growth Rate. This places Pacira BioSciences in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Pacira BioSciences' value of 0.80% is 91.8% below this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 9.80, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 782 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current 3-Year EPS without NRI Growth Rate of 0.80% is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current 3-Year EPS without NRI Growth Rate is 0.80%, which is 92% below median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.31, compared to a current price of $25.53 — trading 12.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.80%, which is 92% below median its 10-year median of 9.45 and 91.8% below the Drug Manufacturers industry median of 9.80. Pacira BioSciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current 3-Year EPS without NRI Growth Rate is 0.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $25.53 is trading 12.9% below its estimated GF Value™ of $29.31.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
3-Year EPS without NRI Growth Rate: 0.80% (92% below median its 10-year median of 9.45)
GF Value™: $29.31 vs. price of $25.53 (12.9% below fair value)
Industry Position: 91.8% below the Drug Manufacturers median (#492 of 782)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
80GF Score
Get the complete analysis for PCRX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
